Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Skewed Caspase-9 Expression Drives Tumorigenicity of Lung Cancer Cells

By LabMedica International staff writers
Posted on 22 Dec 2010
The ability of non-small-cell lung cancer (NSCLC) cells to form tumors and spread is controlled by variations in RNA expression that determine the ratio of pro- and anti-apoptotic forms of the enzyme caspase-9.

Caspase-9 is involved in the intrinsic apoptotic pathway, and it has been implicated as playing a role as a tumor suppressor. However, so far little is known about the mechanisms governing caspase-9 expression.

Investigators at Virginia Commonwealth University (Richmond, USA) worked with a model system in which human NSCLC cells were transplanted into mice. They manipulated this model by using virus-based targeted gene therapy to reduce the amount of heterogeneous nuclear ribonuclear protein family member L (hnRNP L) in the NSCLC cells. HnRNP L is a member of the hnRNP family of RNA processing factors and regulates the expression of two caspase-9 variants, the proapoptotic caspase-a and the antiapoptotic caspase-b, through a process known as RNA splicing.

Results published in the October 25, 2010, online edition of the Journal of Clinical Investigation revealed that the ratio of caspase-9a to caspase-9b differed markedly between normal lung cells and NSCLC cells. Increased caspase-9b in NSCLC cells acted to promote tumor formation, growth, and maintenance. Gene therapy that caused the downregulation of hnRNP L in NSCLC cells induced a complete loss of tumorigenic capacity that was due to the changes in caspase-9 introduced prior to RNA processing. This effect was demonstrated at the molecular level by the finding that hnRNP was specifically phosphorylated in NSCLC. The phosphorylated hnRNP L, in turn, promoted expression the antiapoptotic caspase-9b, thereby contributing to tumorigenesis.

"We are researching an unexplored area of RNA splicing factors in relation to cancer,” said senior author Dr. Charles E. Chalfant, associate professor of biochemistry and molecular biology at Virginia Commonwealth University. "Before this study, there had been very little evidence of an RNA splicing event that results in cancerous tumor development. This study points to caspase-9b as being a very important target in the development of a durable therapy for non-small-cell lung cancer.”

"Unfortunately, many current therapies for lung cancer are less effective and more toxic than we would like,” said Dr. Chalfant. "Lung cancer kills more people than any other cancer, and there is a real need for new cellular targets that are cancer-specific and show results in large numbers of patients regardless of the mutations found in individual tumors. Since caspase-9b is mainly expressed in malignant cells, these findings may provide innovative treatments for non-small-cell lung cancer with little to no toxic side effects.”

Related Links:

Virginia Commonwealth University




Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TETANUS Test
TETANUS VIRCLIA IgG MONOTEST
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.